Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion Danish kroner) to establish a new production facility in Odense, Denmark. The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site.
COPENHAGEN (Reuters) - Danish health authorities said on Monday they would ask the European Union's drug regulator to review ...
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance ...
The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others ...
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
Danish studies have found a potential link between the diabetes drug Ozempic and a rare eye condition called non-arteritic ...
Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...
3don MSN
It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback